Cytokine-Induced Transcription in Depressed Inpatients Undergoing Psychotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06388486

Acronym

CitDip

Enrollment

Registered

2024-04-29

Start date

2017-01-01

Completion date

2024-01-01

Last updated

2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

The goal of this observational study is to measure the levels of cytokine-induced transcription factor activation in a cohort of depressed inpatients undergoing psychotherapy. The study aims to answer the following main questions: * Do psychological traits (i.e.: social inhibition, negative affectivity, ...) affect the activation of immunomodulatory transcription factors (STAT3, NFkB) in depressed patients? * Are subjects with these psychological traits affected differently by psychotherapeutic intervention? Study subjects are assessed for their psychological and behavioral traits and receive psychotherapeutic care over several weeks during hospital treatment. Peripheral blood mononuclear cells are isolated from the study subjects, and activation of transcription factors is measured by flow cytometry.

Detailed description

Study subjects are assessed for their psychological and behavioral traits and receive psychotherapeutic care over several weeks during hospital treatment. Peripheral blood mononuclear cells are isolated from the study subjects, and activation of transcription factors is measured by flow cytometry.

Interventions

BEHAVIORALPsychotherapy

Subject receive psychotherapy during hospital treatment.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of current depression

Exclusion criteria

* inadequate knowledge of the German language * unable to give informed consent * severe psychiatric comorbidities, such as drug abuse and psychotic diseases * deemed critically unstable by their treating physician

Design outcomes

Primary

Measure	Time frame	Description
Change in depression	6 weeks	Hospital Depression and Anxiety Scale (HADS). The HADS instrument is a 14-item scale, with seven items relating to anxiety and seven relating to depression item. Each item on qestionnaire is scored from 0-3 resulting in a score between 0 and 21 for either anxiety or depression with higher scores meaning a worse outcome.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026